NCT03010358View on ClinicalTrials.gov

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

April 29, 2021

Study Completion Date

April 29, 2021

Conditions
AnemiaB-Cell Prolymphocytic LeukemiaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaHairy Cell LeukemiaLymphoplasmacytic LymphomaMantle Cell LymphomaMarginal Zone LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic LymphomaRichter Syndrome
Interventions
DRUG

Entospletinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Obinutuzumab

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

collaborator

Oregon Health and Science University

OTHER

lead

Alexey Danilov, MD

OTHER